Vanguard Group
GBIO

Vanguard Group’s Generation Bio GBIO Stock Holding History

Vanguard Group’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.31M Hold
229,833
– – ﹤0.01% 3704
2025
Q3 		$1.41M Sell
229,833
-2
-0% -$10 ﹤0.01% 3680
2025
Q2 		$735K Sell
229,835
-32,136
-12% -$124K ﹤0.01% 3832
2025
Q1 		$1.06M Sell
261,971
-2,229
-0.8% -$15.7K ﹤0.01% 3691
2024
Q4 		$2.8M Buy
264,200
+628
+0.2% +$11.2K ﹤0.01% 3462
2024
Q3 		$6.51M Buy
263,572
+4,715
+2% +$125K ﹤0.01% 3159
2024
Q2 		$7.3M Buy
258,857
+1,811
+0.7% +$58.8K ﹤0.01% 3078
2024
Q1 		$10.5M Buy
257,046
+1,821
+0.7% +$42.9K ﹤0.01% 2942
2023
Q4 		$4.21M Buy
255,225
+21,347
+9% +$372K ﹤0.01% 3350
2023
Q3 		$8.86M Buy
233,878
+7,952
+4% +$377K ﹤0.01% 2949
2023
Q2 		$12.4M Buy
225,926
+1,661
+0.7% +$76.2K ﹤0.01% 2822
2023
Q1 		$9.64M Buy
224,265
+1,115
+0.5% +$53.9K ﹤0.01% 2953
2022
Q4 		$8.77M Buy
223,150
+1,298
+0.6% +$68.2K ﹤0.01% 3013
2022
Q3 		$11.8M Buy
221,852
+821
+0.4% +$51.4K ﹤0.01% 2873
2022
Q2 		$14.5M Sell
221,031
-133,887
-38% -$8.75M ﹤0.01% 2796
2022
Q1 		$26.1M Sell
354,918
-4,528
-1% -$262K ﹤0.01% 2632
2021
Q4 		$25.4M Buy
359,446
+4,338
+1% +$757K ﹤0.01% 2713
2021
Q3 		$89M Buy
355,108
+32,575
+10% +$7.8M ﹤0.01% 2039
2021
Q2 		$86.8M Buy
322,533
+28,995
+10% +$8.67M ﹤0.01% 2065
2021
Q1 		$83.5M Buy
293,538
+200,893
+217% +$64.3M ﹤0.01% 2048
2020
Q4 		$26.3M Buy
92,645
+7,840
+9% +$2.52M ﹤0.01% 2503
2020
Q3 		$26.2M Buy
84,805
+79,805
+1,596% +$19.1M ﹤0.01% 2325
2020
Q2 		$1.05M Buy
+5,000
New +$1.11M ﹤0.01% 3605

Other funds holding GBIO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group's GBIO Position: Q4 2025 in Review

Vanguard Group held its Generation Bio (GBIO) position steady in Q4 2025 at 229,833 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

Vanguard Group first reported a position in GBIO in Q2 2020 and has held it in 23 quarters since. The position peaked at $89M in Q3 2021. 48 funds tracked by Wall St. Rank hold GBIO as of Q4 2025.

  • Vanguard Group held 229,833 shares of Generation Bio worth $1.31M as of Q4 2025.
  • Vanguard Group left its Generation Bio share count unchanged in Q4 2025.
  • Generation Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3704 holding.
  • Vanguard Group first reported a position in Generation Bio in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Generation Bio position peaked at $89M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Generation Bio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.